Alphamab Oncology — Board/Management Information 2021

Nov 2, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [172 x 40] intentionally omitted <==

ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF CHIEF COMMERCIAL OFFICER

This announcement is made by Alphamab Oncology (the “ Company ”, together with its subsidiaries, the “ Group ”) on a voluntary basis.

The board of directors of the Company (the “ Board ”) is pleased to announce the appointment of Mr. HAN Jing (韓淨) (“ Mr. Han ”) as the chief commercial officer of our Company, primarily responsible for commercial promotion of our Company.

The biographical details of Mr. Han are set out below:

Mr. Han has over 20 years of rich working experience in pharmaceutical sales and marketing in multiple multi-national pharmaceutical companies. Prior to joining our Group, Mr. Han served as senior vice president of Genor Biopharma Co. Ltd, the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) (stock code: 6998), primarily responsible for the establishment of its marketing team and various commercialization matters. From October 2018 to August 2020, Mr. Han served as vice general manager of Shanghai Junshi Biosciences Co., Ltd., the shares of which are listed on the Stock Exchange (stock code: 1877), during which he established the marketing department and was primarily responsible for sales and marketing. In addition, Mr. Han once served as senior sales director of Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司). From 1998 to 2011, Mr. Han was responsible for regional sales and marketing in multiple multi-national pharmaceutical companies, including Bayer Healthcare Company Limited (拜爾醫藥保健有限公司), AstraZeneca Pharmaceutical Co., Ltd. (阿斯利康製藥有限公司) and Hangzhou MSD Pharmaceutical Co., Ltd. (杭州默沙東製藥有 限公司), etc.

1

Mr. Han received his executive master degree of business administration from China Europe International Business School in China, and his bachelor’s degree from the department of clinical medicine of Shanghai Second Medical University (上海市第二醫科大學) (currently known as Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院)) in China.

The Board would like to express its warmest welcome to Mr. Han.

By Order of the Board Alphamab Oncology Dr. XU Ting Chairman and Executive Director

Hong Kong, November 2, 2021

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. Guo Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.

2